This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness data were derived from a single study.
Link between effectiveness and cost data
The costing was carried out prospectively on the same patient sample as that used in the effectiveness study.
Study sample
The sample size was determined using a power analysis set at 80% power to detect a difference of 7 to 10% in quit rates at the p=0.05 level. The CCSS database identified 1,769 current smokers, 1,391 of whom were alive. A further 890 former smokers were also identified from the CCSS survey, of whom 398 were alive and had a known address. Five hundred and twenty-eight of the total identified individuals were not eligible. The PFH team managed to contact 959 of the identified individuals, but were unable to contact 302. A total of 796 were enrolled as participants (83% of the known eligible participants; 63% of the potentially eligible participants) and 162 declined to participate (17% of the known eligible participants; 13% of the potentially eligible participants).
Study design
The study was a randomised controlled trial that was carried out in 22 sites. Details of the methods of randomisation and blinding were not provided. Follow-up was carried out 8 and 12 months after the baseline survey. After 8 months, data were missing for 103 participants in the PC group (56 were lost to further follow-up), and 84 participants in the SH group (36 were lost to further follow-up). After 12 months, data were missing for 102 participants in the PC group (56 were missing at 8 months and 48 were missing only at 12 months) and 2 participants were dead. Data were missing for 76 participants in the SH group (36 were missing at 8 months and 40 were missing only at 12 months).
Analysis of effectiveness
The primary health outcomes measured were: psychosocial variables, measured using the 5-point Likert response scale; readiness to quit smoking, measured using the Stages of Change algorithm; social support, measured using the emotional/informational support sub-scale of the Medical Outcomes Study; perceived vulnerability due to cancer and smoking, assessed using a sub-set of items tapping perceived vulnerability and perceived importance of health protection from Tyc's Perceived Importance of Health Protection scale; knowledge of the risks of smoking for cancer survivors, assessed using the Tobacco Knowledge scale; severity of psychological symptoms, measured using the severity index of the Brief Symptom Inventory (BSI); and perceived health status, measured with one item from the 12-item Short Form Medical Outcomes Study Health Survey.
The analysis was conducted on an intention to treat basis. There was no significant difference between the two intervention groups at analysis.
